Role of thromboxane in producing hepatic injury during hepatic stress

Archives of Surgery

Volumn 140, Issue 8, 2005, Pages 801-807

  Yokoyama, Yukihiro ^a,b   Nimura, Yuji ^a   Nagino, Masato ^a   Bland, Kirby I ^b   Chaudry, Irshad H ^b,c  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Kentucky   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ENDOTHELIN; NITRIC OXIDE; PROSTACYCLIN; THROMBOXANE; VASOACTIVE AGENT;

ALCOHOL LIVER DISEASE; CLINICAL TRIAL; DISEASE MODEL; ENDOTOXEMIA; HEMORRHAGIC SHOCK; HUMAN; LEUKOCYTE ADHERENCE; LIVER CIRRHOSIS; LIVER INJURY; LIVER ISCHEMIA; LIVER RESECTION; LIVER TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; REPERFUSION; RESUSCITATION; REVIEW; STRESS; THROMBOCYTE AGGREGATION; VASOCONSTRICTION;

ANIMALS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; HUMANS; KUPFFER CELLS; LIVER; LIVER CIRCULATION; LIVER DISEASES; MALE; PROGNOSIS; RECEPTORS, THROMBOXANE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; THROMBOXANES;

EID: 23844484346     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.140.8.801     Document Type: Review

References (110)

1. Clemens MG, Bauer M, Pannen BH, et al. Remodeling of hepatic microvascular responsiveness after ischemia/reperfusion. Shock. 1997;8:80-85.
2. Pannen BH, Al-Adili F, Bauer M, et al. Role of endothelins and nitric oxide in hepatic reperfusion injury in the rat. Hepatology. 1998;27:755-764.
3. Kuebler JF, Yokoyama Y, Jarrar D, et al. Administration of progesterone after trauma and hemorrhagic shock prevents hepatocellular injury. Arch Surg. 2003; 138:727-734.
4. Wanner GA, Ertel W, Muller P, et al. Liver ischemia and reperfusion induces a systemic inflammatory response through Kupffer cell activation. Shock. 1996;5:34-40.
5. Andus T, Bauer J, Gerok W. Effects of cytokines on the liver. Hepatology. 1991;13:364-375.
6. Redmond HP, Wang JH, Bouchier-Hayes D. Taurine attenuates nitric oxide- and reactive oxygen intermediate-dependent hepatocyte injury. Arch Surg. 1996;131:1280-1288.
7. Liu P, McGuire GM, Fisher MA, et al. Activation of Kupffer cells and neutrophils for reactive oxygen formation is responsible for endotoxin-enhanced liver injury after hepatic ischemia. Shock. 1995;3:56-62.
8. Jaeschke H, Smith CV, Mitchell JR. Reactive oxygen species during ischemiareflow injury in isolated perfused rat liver. J Clin Invest. 1988;81:1240-1246.
9. Nagai H, Shimazawa T, Yakuo I, et al. The role of thromboxane A2 [TxA2] in liver injury in mice. Prostaglandins. 1989;38:439-446.
10. Zhang JX, Pegoli W Jr, Clemens MG. Endothelin-1 induces direct constriction of hepatic sinusoids. Am J Physiol. 1994;266:G624-G632.
11. Fisher RA, Robertson SM, Olson MS. Stimulation of glycogenolysis and vasoconstriction in the perfused rat liver by the thromboxane A2 analogue U-46619. J Biol Chem. 1987;262:4631-4638.
12. Bataller R, Gines P, Nicolas JM, et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology. 2000;118:1149-1156.
13. Lenzen R, Funk A, Kolb-Bachofen V, et al. Norepinephrine-induced cholestasis in the isolated perfused rat liver is secondary to its hemodynamic effects. Hepatology. 1990;12:314-321.
14. Shah V, Haddad FG, Garcia-Cardena G, et al. Liver sinusoidal endothelial cells are responsible for nitric oxide modulation of resistance in the hepatic sinusoids. J Clin Invest. 1997;100:2923-2930.
15. Mittal MK, Gupta TK, Lee FY, et al. Nitric oxide modulates hepatic vascular tone in normal rat liver. Am J Physiol. 1994;267:G416-G422.
16. Toth B, Yokoyama Y, Kuebler JF, et al. Sex differences in hepatic heme oxygenase expression and activity following trauma and hemorrhagic shock. Arch Surg. 2003;138:1375-1382.
17. Suematsu M, Goda N, Sano T, et al. Carbon monoxide: an endogenous modulator of sinusoidal tone in the perfused rat liver. J Clin Invest. 1995;96:2431-2437.
18. Seelig RF, Kerr JC, Hobson RW II, et al. Prostacyclin (epoprostenol): its effect on canine splanchnic blood flow during hemorrhagic shock. Arch Surg. 1981; 116:428-430.
19. Araki H, Lefer AM. Cytoprotective actions of prostacyclin during hypoxia in the isolated perfused cat liver. Am J Physiol. 1980;238:H176-H181.
20. Baveja R, Zhang JX, Clemens MG. In vivo assessment of endothelin-induced heterogeneity of hepatic tissue perfusion. Shock. 2001;15:186-192.
21. Vo NM, Rikkers LF. Hyperbilirubinemia following distal splenorenal shunt. Arch Surg. 1985;120:301-305.
22. Nanji AA, Khettry U, Sadrzadeh SM, et al. Severity of liver injury in experimental alcoholic liver disease: correlation with plasma endotoxin, prostaglandin E2, leukotriene B4, and thromboxane B2. Am J Pathol. 1993;142:367-373.
23. Katagiri H, Ito Y, Ishii K, et al. Role of thromboxane derived from COX-1 and -2 in hepatic microcirculatory dysfunction during endotoxemia in mice. Hepatology. 2004;39:139-150.
24. Sakamoto S, Okanoue T, Itoh Y, et al. Involvement of Kupffer cells in the interaction between neutrophils and sinusoidal endothelial cells in rats. Shock. 2002;18:152-157.
25. Knoferl MW, Diodato MD, Schwacha MG, et al. Cyclooxygenase-2-mediated regulation of Kupffer cell interleukin-6 production following traumahemorrhage and subsequent sepsis. Shock. 2001;16:479-483.
26. Hla T, Farrell M, Kumar A, et al. Isolation of the cDNA for human prostaglandin H synthase. Prostaglandins. 1986;32:829-845.
27. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci U S A. 1992;89:7384-7388.
28. Ruetten H, Thiemermann C. Effect of calpain inhibitor I, an inhibitor of the proteolysis of I kappa B, on the circulatory failure and multiple organ dysfunction caused by endotoxin in the rat. Br J Pharmacol. 1997;121:695-704.
29. Eum HA, Lee SM. Effect of Trolox on altered vasoregulatory gene expression in hepatic ischemia/reperfusion. Arch Pharm Res. 2004;27:225-231.
30. 2 in early BDL-induced portal hypertension. Am J Physiol Gastrointest Liver Physiol. 2003;284:G453-G460.
31. Nanji AA, Miao L, Thomas P, et al. Enhanced cyclooxygenase-2 gene expression in alcoholic liver disease in the rat. Gastroenterology. 1997;112:943-951.
32. Klein D, Einspanier R, Bolder U, et al. Differences in the hepatic signal transcription pathway and cytokine expression between thermal injury and sepsis. Shock. 2003;20:536-543.
33. Jaeschke H, Smith CW, Clemens MG, et al. Mechanisms of inflammatory liver injury: adhesion molecules and cytotoxicity of neutrophils. Toxicol Appl Pharmacol. 1996;139:213-226.
34. Baveja R, Kresge N, Ashburn JH, et al. Potentiated hepatic microcirculatory response to endothelin-1 during polymicrobial sepsis. Shock. 2002;18:415-422.
35. Nishida J, McCuskey RS, McDonnell D, et al. Protective role of NO in hepatic microcirculatory dysfunction during endotoxemia. Am J Physiol. 1994;267:G1135-G1141.
36. Baveja R, Yokoyama Y, Korneszczuk K, et al. Endothelin 1 impairs oxygen delivery in livers from LPS-primed animals. Shock. 2002;17:383-388.
37. Rieder H, Ramadori G, Allmann KH, et al. Prostanoid release of cultured liver sinusoidal endothelial cells in response to endotoxin and tumor necrosis factor: comparison with umbilical vein endothelial cells. J Hepatol. 1990;11:359-366.
38. 2 receptor antagonist, inhibits tumor necrosis factor-α biosynthesis. Eur J Pharmacol. 1995;286:31-39.
39. Kuhn DC, Stauffer JL, Gaydos LJ, et al. An inhibitor of thromboxane production attenuates tumor necrosis factor release by activated human alveolar macrophages. Prostaglandins. 1993;46:195-205.
40. Tempel GE, Cook JA, Wise WC, et al. Improvement in organ blood flow by inhibition of thromboxane synthetase during experimental endotoxic shock in the rat. J Cardiovasc Pharmacol. 1986;8:514-519.
41. Kawada N, Klein H, Decker K. Eicosanoid-mediated contractility of hepatic stellate cells. Biochem J. 1992;285:367-371.
42. Schirmer WJ, Schirmer JM, Townsend MC, et al. Imidazole and indomethacin improve hepatic perfusion in sepsis. Circ Shock. 1987;21:253-259.
43. Mack Strong VE, Mackrell PJ, Concannon EM, et al. NS-398 treatment after trauma modifies NF-kappaB activation and improves survival. J Surg Res. 2001; 98:40-46.
44. Jaeschke H, Bautista AP, Spolarics Z, et al. Superoxide generation by neutrophils and Kupffer cells during in vivo reperfusion after hepatic ischemia in rats. J Leukoc Biol. 1992;52:377-382.
45. Goto M, Takei Y, Kawano S, et al. Endothelin-1 is involved in the pathogenesis of ischemia/reperfusion liver injury by hepatic microcirculatory disturbances. Hepatology. 1994;19:675-681.
46. Kuroe K, Kurokawa T, Nishikimi M, et al. Effects of thromboxane A2 synthetase inhibitor on postischemic liver injury in rats. Eur Surg Res. 1991;23:20-26.
47. Sunose Y, Takeyoshi I, Ohwada S, et al. The effect of cyclooxygenase-2 inhibitor FK3311 on ischemia-reperfusion injury in a canine total hepatic vascular exclusion model. J Am Coll Surg. 2001;192:54-62.
48. Suehiro T, Yanaga K, Itasaka H, Kishikawa K, Shirabe K, Sugimachi K. Beneficial effect of thromboxane A2 synthetase inhibitor on cold-stored rat liver. Transplantation. 1994;58:768-773.
49. Shirabe K, Kin S, Shinagawa Y, Chen S, Payne WD, Sugimachi K. Inhibition of thromboxane A2 activity during warm ischemia of the liver. J Surg Res. 1996;61:103-107.
50. Hanazaki K, Kuroda T, Haba Y, Shiohara E, Kajikawa S, Iida F. Protective effect of the thromboxane A2 receptor antagonist ONO 3708 on ischemiareperfusion injury in the dog liver. Surgery. 1994;116:896-903.
51. Kim YI, Kai T, Kitano S, et al. Hepatoprotection by a PGI2 analogue in complete warm ischemia of the pig liver: prostanoid release from the reperfused liver. Transplantation. 1994;58:875-879.
52. Kobayashi T, Esato K, Morita N, Noshima NS. Effects of thromboxane A2 synthesis inhibitor (OKY-046) on total liver ischemia in rats. Int Surg. 1996; 81:115-118.
53. Shimada M, Matsumata T, Taketomi A, Shirabe K, Yamamoto K, Sugimachi K. The role of prostaglandins in hepatic resection. Prostaglandins Leukot Essent Fatty Acids. 1994;50:65-68.
54. Iwata M. Pathophysiology of dogs after 84% hepatectomy with emphasis on prostaglandin metabolites and the effect of a thromboxane A2 synthesis inhibitor and a prostaglandin I2 analog. Surg Today. 1994;24:1056-1067.
55. Shirabe K, Takenaka K, Yamamoto K, et al. The role of prostanoid in hepatic damage during hepatectomy. Hepatogastroenterology. 1996;43:596-601.
56. 2and the remnant liver dysfunction after extensive hepatectomy. Surg Today. 1999;29:137-142.
57. Post S, Goerig M, Otto G, et al. Prostanoid release in experimental liver transplantation. Transplantation. 1990;49:490-494.
58. Suehiro T, Boros P, Emre S, et al. Value of caval effluent in predicting early graft function after orthotopic liver transplantation. Transplant Proc. 1997;29:469-470.
59. Yokoyama I, Kobayashi T, Negita M, et al. Liberation of vasoactive substances and its prevention with thromboxane A2 synthase inhibitor in pig liver transplantation. Transpl Int. 1996;9:76-81.
60. Oikawa K, Ohkohchi N, Sato M, Masamume A, Satomi S. Kupffer cells play an important role in the cytokine production and activation of nuclear factors of liver grafts from non-heart-beating donors. Transpl Int. 2002;15:397-405.
61. Ohkohchi N. Suppression of Kupffer cell function is a key for liver transplantation from the non-heart-beating donor. Transplant Proc. 2001;33:3728-3731.
62. Wang P, Ba ZF, Burkhardt J, Chaudry IH. Measurement of hepatic blood flow following trauma and severe hemorrhage with different methods: lack of restoration despite adequate crystalloid resuscitation. Am J Physiol. 1992;262:G92-G98.
63. Wang P, Hauptman JG, Chaudry IH. Hepatocellular dysfunction occurs early after hemorrhage and persists despite fluid resuscitation. J Surg Res. 1990;48:464-470.
64. Yokoyama Y, Toth B, Kitchens WC, Schwacha MG, Bland KI, Chaudry IH. Role of thromboxane in producing portal hypertension following trauma-hemorrhage. Am J Physiol Gastrointest Liver Physiol. 2003;285:G1293-G1299.
65. Rockey DC, Chung JJ. Endothelin antagonism in experimental hepatic fibrosis: implications for endothelin in the pathogenesis of wound healing. J Clin Invest. 1996;98:1381-1388.
66. Gupta TK, Toruner M, Chung MK, Groszmann RJ. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology. 1998;28:926-931.
67. Bhathal PS, Grossman HJ. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol. 1985;1:325-337.
68. Grossman HJ, Grossman VL, Bhathal PS. Enhanced vasoconstrictor response of the isolated perfused cirrhotic rat liver to humoral vasoconstrictor substances found in portal venous blood. J Gastroenterol Hepatol. 1992;7:283-287.
69. Petrowsky H, Schmandra T, Lorey T, Hanisch E, Herrmann G. Endothelininduced contraction of the portal vein in cirrhosis. Eur Surg Res. 1999;31:289-296.
70. Graupera M, Garcia-Pagan JC, Titos E, et al. 5-lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: a possible role of cysteinyl-leukotrienes. Gastroenterology. 2002;122:387-393.
71. Graupera M, Garcia-Pagan JC, Abraldes JG, et al. Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers. Hepatology. 2003;37:172-181.
72. Graupera M, Garcia-Pagan JC, Pares M, et al. Cyclooxygenase-1 inhibition corrects endothelial dysfunction in cirrhotic rat livers. J Hepatol. 2003;39:515-521.
73. 4. Inflamm Res. 2000;49:700-707.
74. Nanji AA, Khwaja S, Rahemtulla A, Miao L, Zhao S, Tahan SR. Thromboxane inhibitors attenuate pathological changes in alcoholic liver disease in the rat. Gastroenterology. 1997;112:200-207.
75. 2 receptors in experimental alcoholic liver disease. J Pharmacol Exp Ther. 1997;282:1037-1043.
76. Myhre U, Pettersen JT, Risoe C, Giercksky KE. Endothelin-1 and endotoxemia. J Cardiovasc Pharmacol. 1993;22(suppl 8):S291-S294.
77. Kawamura E, Yamanaka N, Okamoto E, Tomoda F, Furukawa K. Response of plasma and tissue endothelin-1 to liver ischemia and its implication in ischemiareperfusion injury. Hepatology. 1995;21:1138-1143.
78. Lerman A, Click RL, Narr BJ, et al. Elevation of plasma endothelin associated with systemic hypertension in humans following orthotopic liver transplantation. Transplantation. 1991;51:646-650.
79. Veglio F, Pinna G, Melchio R, et al. Plasma endothelin levels in cirrhotic subjects. J Hepatol. 1992;15:85-87.
80. Rockey DC, Weisiger RA. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology. 1996;24:233-240.
81. Chua CC, Hamdy RC, Chua BH. Regulation of endothelin-1 production by a thromboxane A2 mimetic in rat heart smooth muscle cells. Biochim Biophys Acta. 1996;1313:1-5.
82. 2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells. J Biol Chem. 1994;269:11938-11944.
83. Noveral JP, Rosenberg SM, Anbar RA, Pawlowski NA, Grunstein MM. Role of endothelin-1 in regulating proliferation of cultured rabbit airway smooth muscle cells. Am J Physiol. 1992;263:L317-L324.
84. Reynolds EE, Mok LL. Role of thromboxane A2/prostaglandin H2 receptor in the vasoconstrictor response of rat aorta to endothelin. J Pharmacol Exp Ther. 1990;252:915-921.
85. Kurihara T, Akimoto M, Kurokawa K, et al. Relationship between endothelin and thromboxane A2 in rat liver microcirculation. Life Sci. 1992;51:PL281-PL285.
86. Pang CY, Xu H, Huang N, Forrest CR, Perreault TM, Neligan PC. Amplification effect and mechanism of action of ET-1 in U-46619-induced vasoconstriction in pig skin. Am J Physiol Regul Integr Comp Physiol. 2001;280:R713-R720.
87. Yakubu MA, Leffler CW. Regulation of ET-1 biosynthesis in cerebral microvascular endothelial cells by vasoactive agents and PKC. Am J Physiol. 1999; 276:C300-C305.
88. Rothe CF, Maass-Moreno R. Active and passive liver microvascular responses from angiotensin, endothelin, norepinephrine, and vasopressin. Am J Physiol Heart Circ Physiol. 2000;279:H1147-H1156.
89. Tadros T, Traber DL, Herndon DN. Trauma- and sepsis-induced hepatic ischemia and reperfusion injury: role of angiotensin II. Arch Surg. 2000;135:766-772.
90. Paizis G, Cooper ME, Schembri JM, Tikellis C, Burrell LM, Angus PW. Upregulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology. 2002;123:1667-1676.
91. Araya J, Tsuruma T, Hirata K, Yagihashi A, Watanabe N. TCV-116, an angiotensin II type 1 receptor antagonist, reduces hepatic ischemia-reperfusion injury in rats. Transplantation. 2002;73:529-534.
92. Masuko H, Jin MB, Horiuchi H, et al. Protective effect of agiotensin II type I receptor antagonist, CV-11974, on ischemia and reperfusion injury of the liver. Transplantation. 2001;71:1034-1039.
93. Bataller R, Schwabe RF, Choi YH, et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest. 2003;112:1383-1394.
94. Bataller R, Gabele E, Schoonhoven R, et al. Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. Am J Physiol Gastrointest Liver Physiol. 2003;285:G642-G651.
95. Liu MH, Floten HS, Furnary AP, Yim AP, He GW. Inhibition of vasoconstriction by angiotensin receptor antagonist GR117289C in arterial grafts. Ann Thorac Surg. 2000;70:2064-2069.
96. Ercan ZS, Sindel S, Turker R. Possible thromboxane A2 mediated effect of angiotensin II in the rabbit isolated perfused kidney. Arch Int Physiol Biochim Biophys. 1991;99:397-400.
97. 2 inhibitors and iloprost prevent angiotensin II-induced oedema in the isolated perfused rat lung. Arch Int Pharmacodyn Ther. 1987;287:323-329.
98. 2-mediated pulmonary microvascular dysfunction. Arch Surg. 1999; 134:293-298.
99. Ikeda K, Kubo S, Hirohashi K, et al. Mechanism that regulates nitric oxide production by lipopolysaccharide-stimulated rat Kupffer cells. Physiol Chem Phys Med NMR. 1996;28:239-253.
100. Stadler J, Harbrecht BG, Di Silvio M, et al. Endogenous nitric oxide inhibits the synthesis of cyclooxygenase products and interleukin-6 by rat Kupffer cells. J Leukoc Biol. 1993;53:165-172.
101. Marnett LJ, Wright TL, Crews BC, Tannenbaum SR, Morrow JD. Regulation of prostaglandin biosynthesis by nitric oxide is revealed by targeted deletion of inducible nitric-oxide synthase. J Biol Chem. 2000;275:13427-13430.
102. 2 regulates vascular tone via its inhibitory effect on the expression of inducible nitric oxide synthase. Circulation. 2003;108:2381-2386.
103. Chen CC, Chiu KT, Sun YT, Chen WC. Role of the cyclic AMP-protein kinase A pathway in lipopolysaccharide-induced nitric oxide synthase expression in RAW 264.7 macrophages: involvement of cyclooxygenase-2. J Biol Chem. 1999;274:31559-31564.
104. Carmona RH, Tsao TC, Trunkey DD. The role of prostacyclin and thromboxane in sepsis and septic shock. Arch Surg. 1984;119:189-192.
105. Haba Y, Kuroda T. Thromboxane A2 receptor antagonist (ONO 3708) protects from liver damage induced by cholestasis and ischemia-reperfusion. Eur Surg Res. 1995;27:100-110.
106. Besse T, Gustin T, Claeys N, Schroeyers P, Lambotte L. Effect of PGI2 and thromboxane antagonist on liver ischemic injury. Eur Surg Res. 1989;21:213-217.
107. Neumann UP, Kaisers U, Langrehr JM, et al. Administration of prostacyclin after liver transplantation: a placebo controlled randomized trial. Clin Transplant. 2000;14:70-74.
108. 1 and IP receptors. Br J Pharmacol. 2000;131:601-609.
109. 2 receptor is a target for prostacyclin-mediated desensitization. J Biol Chem. 2000;275:20412-20423.
110. Fennekohl A, Schieferdecker HL, Jungermann K, Puschel GP. Differential expression of prostanoid receptors in hepatocytes, Kupffer cells, sinusoidal endothelial cells and stellate cells of rat liver. J Hepatol. 1999;30:38-47.